Back
Full-text
Journal article

Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.

Show more…
  • 2009-01-13
Published in:
  • Breast cancer research and treatment. - 2009
Aged
Aged, 80 and over
Antineoplastic Agents, Hormonal
Breast Neoplasms
Chemotherapy, Adjuvant
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Neoplasm Recurrence, Local
Randomized Controlled Trials as Topic
Receptors, Estrogen
Treatment Outcome
English The current therapeutic strategy in breast cancer is to identify a target, such as estrogen receptor (ER) status, for tailoring treatments. We investigated the patterns of recurrence with respect to ER status for patients treated in two randomized trials with 25 years' median follow-up. In the ER-negative subpopulations most breast cancer events occurred within the first 5-7 years after randomization, while in the ER-positive subpopulations breast cancer events were spread through 10 years. In the ER-positive subpopulation, 1 year endocrine treatment alone significantly prolonged disease-free survival (DFS) with no additional benefit observed by adding 1 year of chemotherapy. In the small ER-negative subpopulation chemo-endocrine therapy had a significantly better DFS than endocrine alone or no treatment. Despite small numbers of patients, "old-fashioned" treatments, and competing causes of treatment failure, the value of ER status as a target for response to adjuvant treatment is evident through prolonged follow-up.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/209327
Statistics
Document views: 16 File downloads:
  • fulltext.pdf: 0